The CXCL13 signature and the 12-chemokine signature were also significantly enriched in neoadjuvant tumor lesions, indicating increased lymphocytes infiltration and TLS formation after neoadjuvant chemoimmunotherapy (Fig. 3A). The gene discussed is CXCL13; the disease is neoplasm.